FDA Approves New Treatment For Adults With Relapsed Or Refractory Large-B-Cell Lymphoma - PRNewswire

FDA Approves New Treatment For Adults With Relapsed Or Refractory Large-B-Cell Lymphoma  PRNewswireBristol Myers Squibb's CAR-T liso-cel wins long-delayed FDA nod  FiercePharmaLiso-cel Receives FDA Approval for the Treatment of R/R Large B-Cell Lymphoma  Cancer NetworkU.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel), a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma  B